bluebird bio (BLUE) Misses Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Bluebird Bio (BLUE) PT Lifted to $119 at Piper Jaffray
February 26, 2015 8:43 AM ESTPiper Jaffray analyst Joshua Schimmer raised his price target on Overweight-rated Bluebird Bio (NASDAQ: BLUE) to $119.00 (from $112.00) following Q4 earnings.
Schimmer commented, "BLUE released 4Q14 earnings Wednesday evening disclosing a cash/cash equivalent balance of $492.0M. The company continues to advance its... More
